Numinus Wellness Sells Off Shares In Alto Neuroscience Ahead Of IPO

Numinus Wellness (TSX: NUMI) is reporting this morning that it has sold its interest in Alto Neuroscience, a clinical-stage biopharma company that filed for its initial public offering earlier this week.

Alto’s current biotech pipeline is centered on tackling depression, with three clinical-stage programs currently underway, including one for its lead drug, ALTO-100. The drug is in a phase 2b trial, with results expected in the second half of the year.

The company is currently expected to raise between $93.8 and $107.2 million in gross proceeds from its go public, selling 6.7 million shares in a range of $14 to $16 a piece.

Numinous meanwhile held 1,000 non-voting participation shares of Alto within a special purpose vehicle, which Novamind, whom Numinus previously acquired, purchased at a price of $1.22 million. It is unclear at what ratio these shares would have converted into common stock. The fair value of the holdings were reported as being $1.6 million as of November 30, 2023.

“As our core strategy is to build the critical infrastructure that addresses the growing need for effective mental health treatments, the proceeds from the sale of this non-core asset will provide additional financial liquidity and flexibility,” commented Payton Nyquvest on the sale.

Total proceeds from the sale by Numinus were not disclosed.

Numinus Wellness last traded at $0.14 on the TSX.


Information for this briefing was found via Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Are We Entering a New 10-Year Silver Supercycle? | Keith Neumeyer – First Majestic Silver

Why the Biggest Players Are Desperate for New Gold & Copper, And Fast | Rudi Fronk – Seabridge

Why the World Faces a Uranium Supply Shock, Sooner Than You Think | Scott Melbye – Uranium Royalty

Recommended

ESGold Sees ANT Survey Reveal Vertically Continuous System To 1,200 Metres Depth

First Majestic Produces 7.9 Silver Equivalent Ounces In Q2, Lifts Production Guidance

Related News

Numinus Wellness To Acquire Novamind In All Stock Transaction At $0.44 Per Share

Consolidation within the psychedelics space is getting underway, with the announcement this morning that Numinus...

Tuesday, April 12, 2022, 07:56:51 AM

Numinus Wellness Announces Move To Toronto Stock Exchange

Numinus Wellness (TSV: NUMI) is set to be one of the next firms listed on...

Friday, November 26, 2021, 09:26:00 AM

Numinus Wellness To Undertake Phase 1 Study Of Psilocybin Extract

Numinus Wellness (TSXV: NUMI) is undertaking further studies of its psilocybin products. The company this...

Monday, April 26, 2021, 07:10:35 AM

Numinus Sees Integrated VC, MAPS Lead $6.0 Million Funding Round

Numinus Wellness (TSX: NUMI) has received a major vote of confidence, announcing last night that...

Friday, February 2, 2024, 09:00:02 AM

Numinus Wellness Walks From Acquisition Of MedBright AI

Numinus Wellness (TSX: NUMI) has walked away from a plan to add artificial intelligence assets...

Monday, August 12, 2024, 10:08:35 AM